NCT06016569 Study of Early Cancer Biomarkers in Breath Condensate in Population of Individuals With High-Risk of Lung Cancer Undergoing LDCT Screening.
| NCT ID | NCT06016569 |
| Status | Recruiting |
| Phase | — |
| Sponsor | The Institute of Molecular and Translational Medicine, Czech Republic |
| Condition | Lung Cancer |
| Study Type | INTERVENTIONAL |
| Enrollment | 3,200 participants |
| Start Date | 2023-06-01 |
| Primary Completion | 2029-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 3,200 participants in total. It began in 2023-06-01 with a primary completion date of 2029-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The trial will evaluate if the newly identified biomarkers of lung cancer in exhaled breath condensate are as a diagnostic tool comparable to the low-dose computer tomography (LDCT) implemented in lung cancer screening recently. Due to the possibility to collect breath condensate at any medical workplace and due to the relatively low financial cost of examination of the collected breath condensate could improve early diagnosis of lung cancer, differential diagnostics of lung nodules and thereby reduce both the unnecessary interventions and deaths from this type of cancer.
Eligibility Criteria
Inclusion Criteria: 1. Consent to participate in a clinical trial. 2. A clients within an age of 55-74 years. 3. Current smoker or ex-smoker who has smoked at least 20 pack-years, provided that: 1. priority will be given to clients who have smoked at least 30 pack-years. 2. preference will be given to a former smoker who has not smoked for less than 15 years. Exclusion Criteria: 1. Previous diagnosis of lung cancer. 2. Progressing malignant tumor on symptomatic treatment. 3. Advanced dementia 4. Chronic obstructive pulmonary disease or other inflammatory disease in the phase of acute exacerbation.
Contact & Investigator
Marian Hajduch, MD, PhD.
STUDY DIRECTOR
IMTM, Palacky University in Olomouc, Faculty of Medicine and Dentistry
Frequently Asked Questions
Who can join the NCT06016569 clinical trial?
This trial is open to participants of all sexes, aged 55 Years or older, up to 74 Years, studying Lung Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06016569 currently recruiting?
Yes, NCT06016569 is actively recruiting participants. Contact the research team at marian.hajduch@upol.cz for enrollment information.
Where is the NCT06016569 trial being conducted?
This trial is being conducted at Brno, Czechia, Olomouc, Czechia, Prague, Czechia.
Who is sponsoring the NCT06016569 clinical trial?
NCT06016569 is sponsored by The Institute of Molecular and Translational Medicine, Czech Republic. The principal investigator is Marian Hajduch, MD, PhD. at IMTM, Palacky University in Olomouc, Faculty of Medicine and Dentistry. The trial plans to enroll 3,200 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.